RASTETTER WILLIAM H

Director William H Rastetter sold 18,000 NBIX shares at $151.82 for $2.7M, reducing holdings 30.8% near 52-week highs amid +23.8% 90-day rally.

Director Rastetter sold 18,000 shares (30.8% of pre-transaction holdings) at $151.82 on 2025-11-05, executing near the 52-week high of $154.80 during a strong momentum period—the stock had gained 23.8% over 90 days and 13.0% over 30 days. His cross-ticker track record shows 3 prior sells with a 90-day well-timed rate of 50.00%, while his same-ticker history at NBIX shows mixed outcomes: the prior sell on 2025-05-05 was followed by +17.0% 90-day gains (poorly timed), and the 2024-08-15 sale was followed by -14.4% 90-day returns (well-timed), suggesting no consistent predictive pattern at this ticker. The stock remains strong fundamentally with +24.8% annual revenue growth, $209.5M net income, and a P/E of 36.08. This sale occurred during a period of elevated valuation and stock strength, reducing his exposure materially from 58,360 to 40,360 shares.

Director William H. Rastetter sold 30,000 NBIX shares at $110.20 on 2025-05-05, reducing holdings by 44.5%

Rastetter executed a substantial share reduction, selling 30,000 shares (44.5% of his pre-transaction holdings of 67,491 shares) at $110.20, leaving him with 37,491 shares post-trade. His prior NBIX sale on 2024-08-15 posted a -14.4% 90-day return, consistent with his cross-ticker track record's 90d average of -14.4%, where 100.00% of his prior sells were well-timed at the 90-day horizon. The current price of $121.61 sits 20.7% below the 52-week high of $153.29, suggesting the stock has retreated from recent peaks despite strong fundamentals: NBIX reported $572.6M in latest-quarter revenue with 24.8% annual growth and a $12.0B market cap, though the P/E of 39.36 reflects high valuation expectations. The 44.5% reduction in holdings is notable in scale relative to his historical patterns.

Director William Rastetter sold 14,250 NBIX shares at $146.69 for $2.1M on 2024-08-15, reducing stake by 27.5%

William Rastetter, a Director at Neurocrine Biosciences, sold 14,250 shares at $146.69, reducing his holdings from 51,741 shares to 37,491 shares—a substantial 27.5% reduction. The stock currently trades at $145.01, near the top of its 52-week range of $104.30–$153.15. His prior sell at this ticker on 2024-01-02 saw a 90-day return of +7.5%, indicating the stock moved upward after that sale; this transaction follows a similar pattern where the company has shown strong fundamentals with annual revenue growth of +26.8% and net income of $65.0M on quarterly revenue of $590.2M. The scale of this reduction—nearly 28% of his prior position—alongside solid operational metrics and stock price strength near its annual highs suggests a substantial and deliberate portfolio adjustment rather than a routine position refinement.